Acceptance and Commitment Therapy in Tuberous Sclerosis Complex

University Hospitals Bristol and Weston NHS Foundation Trust15 enrolled

Overview

The study will assess the acceptability and feasibility of a randomised controlled trial of 6-12 sessions of remotely-delivered Acceptance and Commitment Therapy (ACT) versus waitlist control. Waitlist control will involve a delay in the offer of ACT sessions for 12 weeks. Participants may access all services as usual in this time. Follow-up assessments will be conducted at 12-, 24 and 48 weeks post-randomisation to measure effectiveness.

Tuberous Sclerosis Complex (TSC) is a genetic disease caused by mutations in the tumour suppressor genes TSC1 and TSC2. The clinical hallmarks of the disease are the growth of benign tumours in various organs such as the brain, kidneys and skin. Seizures are present in around 60% of the population and neurodevelopmental problems such as attention deficit disorder and autism are common. Anxiety and depressive disorders are similarly linked and at the psychosocial level, there is increasing evidence of the effect of TSC on self-esteem, family functioning and peer relationships resulting in poorer quality of life. Despite these difficulties, no unique treatments, and almost no effective evidenced psychological treatments for TSC are available. This trial aims to assess the feasibility and acceptability of Acceptance and Commitment Therapy (ACT) as a psychological treatment to improve quality of life among adolescents and young adults with TSC. ACT is a cognitive behavioural therapy that helps participants accept difficulties that they are unable to change. There is strong evidence for ACT's clinical effectiveness amongst patients with chronic diseases. The intervention will be delivered to participants aged 11-24 with TSC and sufficient cognitive and speech capabilities to take part. This will be delivered remotely via secure video-conferencing software. Our primary hypothesis is that ACT will be acceptable and feasible delivered remotely and may yield clinical improvements in health and quality of life. The study will be a 12-week, waitlist controlled randomised clinical trial. Participants will be randomised to receive 12-weeks treatment either immediately or following a 12-week wait. The treatment will be ACT adapted for 11-24-year olds who have TSC. Treatment will involve 6 to 12 weekly sessions of ACT of up to one hour each in length. Clinical outcomes will be assessed unblinded at baseline, 12, 24 and 48 weeks from randomisation. As a feasibility and acceptability study a range of physical and mental health outcomes are assessed. All clinical outcomes focus on health, wellbeing and quality of life from baseline to 12 week (3-month) follow-up amongst those offered ACT immediately versus waitlist controls.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Tuberous Sclerosis Complex

Interventions

Acceptance and Commitment Therapy (ACT)BEHAVIORAL

Acceptance and commitment therapy (ACT) is an evidence-based psychological therapy that has been successfully used to improve physical and mental health among children and adults with chronic conditions. It is a "third wave" cognitive behavioural therapy that encourages openness to and awareness of the present moment in order to help participants maintain behaviours consistent with their life goals. ACT fosters engagement with, rather than avoidance of, painful experiences to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing difficulties. This gives ACT strong face validity for application to TCS patients where there can be permanent cognitive impairment and unavoidable ongoing physical symptoms and functional limitations.

Eligibility

Sex: ALLMin age: 11 YearsMax age: 24 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Aged 11 to 24 years. * Diagnosis of Tuberous Sclerosis Complex. * Sufficient understanding of English to engage with the intervention (spoken and written), as judged by the assessing clinician. * Sufficient cognitive, sensory and speech capabilities to take part in the intervention. * Participants (or their parents if under 16) give verbal or written informed consent to participate in the study. * Participants give verbal or written assent if under 16. * Receiving treatment over video-conferencing will be the default modality for delivery, so access to the internet is a requirement. Exclusion Criteria: * Previous structured behavioural intervention within last 6 months. * Previous or current alcohol/substance dependence, psychosis, suicidality, or anorexia nervosa. * Moderate or severe intellectual disability. * Immediate risk to self or others. * Parent or child not able to speak, read or write English.

Locations (1)

University Hospitals Bristol and Weston NHS Trust

Bristol, United Kingdom

Outcomes

Primary Outcomes

Treatment completion rate

The proportion of patients showing interest who then consent to the trial and complete the intervention.

Time frame: Assessed at 3-month follow-up.

Treatment completion rate

The proportion of patients showing interest who then consent to the trial and complete the intervention.

Time frame: Assessed at 6-month follow-up

Session attendance rate

The session attendance rate compared to feasibility benchmarks.

Time frame: Assessed at 3-month follow-up

Session attendance rate

The session attendance rate compared to feasibility benchmarks.

Time frame: Assessed at 6-month follow-up

The credibility/expectancy questionnaire

Assessing participant ratings of treatment credibility. Minimum score = 5; maximum score = 45. Higher scores indicate better outcome.

Time frame: Assessed at baseline

The credibility/expectancy questionnaire

Assessing participant ratings of treatment credibility. Minimum score = 5; maximum score = 45. Higher scores indicate better outcome.

Time frame: Assessed at session 2

The experience of service questionnaire

A questionnaire used nationally in child and adolescent mental health services completed by patients and parents/carers (if under 16) to assess participants' experience of the intervention. An additional item has been added to the experience of service questionnaire to assess video-conferencing treatment satisfaction. Minimum score = 0; maximum score = 20. Higher scores indicate better outcome.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Acceptance and Action Questionnaire II

A brief 7-item self-report measure assessing psychological inflexibility, which is the central treatment target for ACT. Validated for use among patients aged 16 and over. Minimum score = 7; maximum score = 49. Higher scores indicate worse outcome.